This strategy blocks checkpoint signaling pathways, including CD47/SIRPα and PD-1/PD-L1, thereby activating cancer photoimmunotherapy and reinvigorating antitumor macrophages and T cells [170]. This evidence concerns the gene CD47 and cancer.